Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biotechnology Equipment

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1333404

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1333404

Next Generation Sequencing (NGS) Data Analysis

PUBLISHED:
PAGES: 437 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach $2.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$738.5 Million in the year 2022, is projected to reach a revised size of US$2.1 Billion by 2030, growing at aCAGR of 13.9% over the period 2022-2030. Services, one of the segments analyzed in the report, is projected to record 14.8% CAGR and reach US$1.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the NGS Commercial Software segment is readjusted to a revised 12.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $279.7 Million, While China is Forecast to Grow at 15.2% CAGR

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$279.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$229.2 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 13.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Select Competitors (Total 111 Featured) -

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL (Advanced Biological Laboratories) SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics
Show more
Product Code: MCP22378

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Next Generation Sequencing (NGS) Data Analysis - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • NGS Data Analysis: Unraveling Critical Clues to Solve Scientific Problems
    • NGS Data Analysis: Insights into File Formats & Downstream Analysis
    • File Formats for NGS Raw Data
    • NGS Data: Downstream Analysis
    • Impact of Covid-19 and a Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • Scientists Seek to Gather More Information on Omicron
    • The Never-Ending "Race" Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
    • Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
    • Short-term Impact of Omicron on Travel
    • Financial Impact
    • Scientists Seek to Gather More Information on Omicron
    • Scientists Seek to Gather More Information on Omicron
    • Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
    • Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
    • Omicron: Impact on Travel Industry
    • Steps taken by the Countries to Prevent Transmission of Omicron Variant
    • With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
    • A Strong Yet Exceedingly Patchy & Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • Impact of COVID-19 on Next Generation Sequencing (NGS) Data Analysis
    • Great Promise of NGS in Fight against COVID-19 Brings Spotlight on NGS Data Analysis Market
    • Global Market Overview and Prospects
    • Next-Generation Sequencing (NGS) Data Analysis Market Witnesses Burgeoning Growth
    • Key Market Drivers and Inhibitors
    • Market Analysis
    • US and Europe Lead, Asia-Pacific to Witness Growth
    • Analysis by Product
    • Analysis by Workflow
    • Analysis by Mode
    • Analysis by Read Length
    • Analysis by End-Use
    • Competitive Landscape
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Next Generation Sequencing Market Drives the Demand for NGS Data Analysis
    • Increasing R&D Activities in NGS
    • Rising Use of NGS in Drug Discovery Drives Growth of NGS Data Analysis
    • Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
    • Technological Advancements in Sequencing Techniques and Data Integration
    • Research Initiatives for the Development of NGS-based In-vitro Diagnostics
    • The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
    • NGS Data Analysis Using Big Data Gains Ground
    • Improving Regulatory & Reimbursement Scenario for NGS-based Diagnostic Tests
    • Increase in Genome Mapping Programs
    • Declining Costs of Genome Sequencing Drive Market Growth
    • Growth of Long-Read Sequencing to Propel the Market for NGS Data Analysis
    • Aging Demographics Present Opportunities
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Growing Prevalence of Chronic Diseases to Boost the Market Prospects
    • Rising Diabetes Prevalence: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Breakdown of Total Number of Cancer Cases by Region: 2020
    • Breakdown of Total Number of Cancer Cases by Type: 2020
    • Market Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ngs Commercial Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Ngs Commercial Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World 8-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World 8-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 22: World 8-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 24: World 8-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 26: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 27: World Next Generation Sequencing (NGS) Data Analysis Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: USA 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: USA 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Canada 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Canada 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Canada 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • JAPAN
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Japan 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Japan 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • CHINA
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: China 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: China 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: China 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • EUROPE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 61: Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • FRANCE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 71: France 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 73: France 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 77: France 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • GERMANY
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Germany 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Germany 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Germany 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Italy 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Italy 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Italy 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • UNITED KINGDOM
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 94: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 95: UK 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 97: UK 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: UK 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 101: UK 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Rest of World 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2023 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Rest of World 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2023 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of World 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2023 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 125: Rest of World 8-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!